60.00
price up icon3.34%   1.94
pre-market  Pre-mercato:  59.89   -0.11   -0.18%
loading
Precedente Chiudi:
$58.06
Aprire:
$58.82
Volume 24 ore:
1.17M
Relative Volume:
0.69
Capitalizzazione di mercato:
$5.76B
Reddito:
$3.51M
Utile/perdita netta:
$-581.60M
Rapporto P/E:
-9.2102
EPS:
-6.5145
Flusso di cassa netto:
$-345.93M
1 W Prestazione:
+8.70%
1M Prestazione:
+19.59%
6M Prestazione:
+13.77%
1 anno Prestazione:
+38.09%
Intervallo 1D:
Value
$57.75
$60.60
Intervallo di 1 settimana:
Value
$53.75
$61.76
Portata 52W:
Value
$30.04
$78.48

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name
Nome
Crispr Therapeutics Ag
Name
Telefono
(617) 315-4600
Name
Indirizzo
BAARERSTRASSE 14, ZUG
Name
Dipendente
393
Name
Cinguettio
@crisprtx
Name
Prossima data di guadagno
2025-10-31
Name
Ultimi documenti SEC
Name
CRSP's Discussions on Twitter

Compare CRSP vs VRTX, REGN, ARGX, ALNY, ONC

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CRSP
Crispr Therapeutics Ag
60.00 5.57B 3.51M -581.60M -345.93M -6.5145
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.89 120.48B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
787.50 81.05B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
749.56 46.33B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.30 42.26B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.02 32.87B 5.36B 287.73M 924.18M 2.5229

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-09-18 Iniziato JP Morgan Overweight
2025-02-14 Aggiornamento Evercore ISI In-line → Outperform
2025-02-12 Aggiornamento TD Cowen Sell → Hold
2025-02-03 Iniziato H.C. Wainwright Buy
2024-08-06 Reiterato Needham Buy
2024-08-02 Iniziato Rodman & Renshaw Buy
2024-06-28 Ripresa Guggenheim Neutral
2024-02-15 Iniziato Wolfe Research Peer Perform
2023-12-11 Downgrade TD Cowen Market Perform → Underperform
2023-10-17 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-09-27 Iniziato Mizuho Buy
2023-08-17 Aggiornamento Citigroup Neutral → Buy
2023-05-30 Iniziato William Blair Outperform
2023-04-13 Iniziato Cantor Fitzgerald Overweight
2023-03-21 Iniziato Bernstein Mkt Perform
2023-03-17 Iniziato Bryan Garnier Buy
2023-03-07 Iniziato Robert W. Baird Neutral
2022-10-11 Iniziato Morgan Stanley Underweight
2022-08-09 Downgrade Barclays Overweight → Equal Weight
2022-06-23 Downgrade Evercore ISI Outperform → In-line
2022-06-17 Iniziato BMO Capital Markets Outperform
2022-04-28 Iniziato Credit Suisse Neutral
2021-12-07 Iniziato Cowen Market Perform
2021-10-19 Iniziato SVB Leerink Outperform
2021-06-14 Aggiornamento Citigroup Sell → Neutral
2021-04-21 Aggiornamento Jefferies Hold → Buy
2021-03-04 Iniziato JMP Securities Mkt Outperform
2020-12-10 Reiterato Chardan Capital Markets Buy
2020-12-10 Downgrade Jefferies Buy → Hold
2020-12-10 Reiterato Needham Buy
2020-12-07 Downgrade Wells Fargo Overweight → Equal Weight
2020-10-23 Iniziato RBC Capital Mkts Sector Perform
2020-10-05 Iniziato BofA Securities Buy
2020-07-28 Reiterato Needham Buy
2020-07-14 Iniziato SunTrust Buy
2020-06-15 Reiterato Canaccord Genuity Buy
2020-03-05 Iniziato Stifel Hold
2020-02-03 Downgrade Evercore ISI Outperform → In-line
2019-11-19 Aggiornamento William Blair Mkt Perform → Outperform
2019-11-12 Aggiornamento Oppenheimer Perform → Outperform
2019-08-01 Iniziato Jefferies Buy
2019-07-26 Iniziato Canaccord Genuity Buy
2019-06-10 Iniziato ROTH Capital Buy
2019-04-12 Iniziato Evercore ISI Outperform
2019-03-14 Iniziato William Blair Mkt Perform
2019-01-28 Downgrade Goldman Buy → Neutral
2019-01-22 Downgrade Citigroup Neutral → Sell
Mostra tutto

Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie

pulisher
03:36 AM

Amova Asset Management Americas Inc. Decreases Position in CRISPR Therapeutics AG $CRSP - MarketBeat

03:36 AM
pulisher
03:36 AM

CRISPR Therapeutics AG $CRSP is ARK Investment Management LLC's 8th Largest Position - MarketBeat

03:36 AM
pulisher
Mar 04, 2026

Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of - The Motley Fool

Mar 04, 2026
pulisher
Mar 04, 2026

CRISPR Therapeutics AG $CRSP Position Raised by Vanguard Group Inc. - MarketBeat

Mar 04, 2026
pulisher
Mar 03, 2026

Contrarius Group Holdings Ltd Sells 104,604 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

CRSP Stock Price and Chart — NASDAQ:CRSP - TradingView

Mar 03, 2026
pulisher
Mar 02, 2026

Here’s What You Should Understand Besides the Reason CRISPR Therapeutics AG (CRSP) is Gaining Attention - Bitget

Mar 02, 2026
pulisher
Mar 02, 2026

Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? - The Motley Fool

Mar 02, 2026
pulisher
Mar 02, 2026

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - Yahoo Finance

Mar 02, 2026
pulisher
Mar 02, 2026

TD Asset Management Inc Sells 53,800 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

Rafferty Asset Management LLC Has $10 Million Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat

Mar 02, 2026
pulisher
Mar 02, 2026

Vertex Interest Renews CRISPR Therapeutics Takeover Talk And Investor Questions - Sahm

Mar 02, 2026
pulisher
Mar 01, 2026

HighTower Advisors LLC Reduces Stake in CRISPR Therapeutics AG $CRSP - MarketBeat

Mar 01, 2026
pulisher
Mar 01, 2026

symbol__ Stock Quote Price and Forecast - CNN

Mar 01, 2026
pulisher
Feb 28, 2026

FDA Draft Guidance Puts CRISPR Therapeutics Gene Editing Outlook In Focus - Sahm

Feb 28, 2026
pulisher
Feb 28, 2026

Crispr Therapeutics AG Surges on Takeover Buzz and Hype - TipRanks

Feb 28, 2026
pulisher
Feb 28, 2026

JPMorgan Chase & Co. Buys 294,222 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat

Feb 28, 2026
pulisher
Feb 28, 2026

CRISPR Therapeutics Takeover Chatter With Vertex Puts Investor Tradeoffs In Focus - Sahm

Feb 28, 2026
pulisher
Feb 28, 2026

Here’s What Analysts Are Saying About CRISPR Therapeutics AG (CRSP) - Yahoo Finance

Feb 28, 2026
pulisher
Feb 27, 2026

CRISPR Therapeutics Hits Day High with 11.85% Surge in Stock Price - Markets Mojo

Feb 27, 2026
pulisher
Feb 27, 2026

CRISPR Therapeutics Shares Surge on Strong Earnings and Pipeline Growth - Intellectia AI

Feb 27, 2026
pulisher
Feb 27, 2026

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch - TechStock²

Feb 27, 2026
pulisher
Feb 26, 2026

Crispr Therapeutics (CRSP) Shares Surge on Takeover Speculation - GuruFocus

Feb 26, 2026
pulisher
Feb 26, 2026

CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 11.2%Still a Buy? - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Why Is CRISPR Therapeutics Stock Surging Thursday? - Benzinga

Feb 26, 2026
pulisher
Feb 26, 2026

Crispr Therapeutics (CRSP) Rumored in M&A Discussions Once More - GuruFocus

Feb 26, 2026
pulisher
Feb 26, 2026

Rumor Mill Sends Crispr Therapeutics Shares Climbing Again - TipRanks

Feb 26, 2026
pulisher
Feb 26, 2026

Assessing CRISPR Therapeutics (CRSP) Valuation After FDA Draft Guidance And Recent Weak Earnings - Yahoo Finance

Feb 26, 2026
pulisher
Feb 26, 2026

CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Feb 26, 2026
pulisher
Feb 25, 2026

Should You Buy Shares of CRISPR Therapeutics in February? - aol.com

Feb 25, 2026
pulisher
Feb 25, 2026

CRISPR Therapeutics AG (CRSP) Stock Analysis: Unveiling A 57% Potential Upside - DirectorsTalk Interviews

Feb 25, 2026
pulisher
Feb 24, 2026

CRISPR Therapeutics AG Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Feb 24, 2026
pulisher
Feb 24, 2026

Versant Venture Management LLC Decreases Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat

Feb 24, 2026
pulisher
Feb 24, 2026

FDA's New Framework Could Benefit CRISPR Therapeutics (CRSP) - GuruFocus

Feb 24, 2026
pulisher
Feb 23, 2026

(CRSP) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Feb 23, 2026
pulisher
Feb 23, 2026

CRISPR Therapeutics gains after earnings as pipeline hope grows - MSN

Feb 23, 2026
pulisher
Feb 23, 2026

Rare disease pharmas could benefit from FDA guidance to accelerate development - Seeking Alpha

Feb 23, 2026
pulisher
Feb 23, 2026

Volume Report: Will CRISPR Therapeutics AG benefit from sector rotation2025 Technical Overview & Fast Exit and Entry Strategy Plans - baoquankhu1.vn

Feb 23, 2026
pulisher
Feb 23, 2026

O Neil Global Advisors Inc. Acquires Shares of 168,715 CRISPR Therapeutics AG $CRSP - MarketBeat

Feb 23, 2026
pulisher
Feb 23, 2026

How FDA RMAT Status For Zugo-cel Amid Wider Losses At CRISPR Therapeutics (CRSP) Has Changed Its Investment Story - simplywall.st

Feb 23, 2026
pulisher
Feb 22, 2026

Vestmark Advisory Solutions Inc. Has $15.49 Million Stake in CRISPR Therapeutics AG $CRSP - MarketBeat

Feb 22, 2026
pulisher
Feb 20, 2026

CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $111,048.96 in Stock - MarketBeat

Feb 20, 2026
pulisher
Feb 20, 2026

CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $366,324.86 in Stock - MarketBeat

Feb 20, 2026
pulisher
Feb 20, 2026

CRISPR Therapeutics (CRSP) CEO sells shares to cover RSU taxes - Stock Titan

Feb 20, 2026
pulisher
Feb 20, 2026

Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? - The Motley Fool

Feb 20, 2026
pulisher
Feb 20, 2026

First Week of October 16th Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq

Feb 20, 2026
pulisher
Feb 20, 2026

The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices - The Motley Fool

Feb 20, 2026
pulisher
Feb 19, 2026

What’s next for CRISPR Therapeutics AG stockJuly 2025 Setups & Verified Entry Point Detection - mfd.ru

Feb 19, 2026
pulisher
Feb 19, 2026

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street - AOL.com

Feb 19, 2026
pulisher
Feb 19, 2026

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows - sharewise.com

Feb 19, 2026
pulisher
Feb 19, 2026

Casgevy Rollout And Pipeline Progress Reshape CRISPR Therapeutics Investment Case - Yahoo Finance

Feb 19, 2026

Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$47.43
price down icon 0.11%
$29.52
price up icon 6.00%
$57.80
price up icon 15.99%
$103.80
price up icon 3.02%
$149.88
price up icon 1.96%
biotechnology ONC
$299.02
price up icon 0.67%
Capitalizzazione:     |  Volume (24 ore):